Recent News

• 11.24.2025 - Data from Genprex’s Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
• 11.19.2025 - Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
• 11.18.2025 - Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
• 11.04.2025 - Genprex Announces European Patent Office’s Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
• 10.28.2025 - Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
• 10.28.2025 - Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Recent Filings

• 11.21.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.21.2025 - 8-K Current report
• 11.21.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 11.19.2025 - 8-K Current report
• 11.18.2025 - 8-K Current report
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.14.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.04.2025 - 8-K Current report
• 11.03.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors